Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

Blood (2025) 146 (Supplement 1): 2395.

https://doi.org/10.1182/blood-2025-2395

Published: 2025

Journal Articles

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Tingting Yang, Mingming Zhang, Mengqi Yu, Shan Fu, Jingjing Feng, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 1040.

https://doi.org/10.1182/blood-2025-1040

Published: 2025

Journal Articles

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

Mingming Zhang, Lianxuan Liu, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Zhang, He Huang

Blood (2025) 146 (Supplement 1): 1940.

https://doi.org/10.1182/blood-2025-1940

Published: 2025

Journal Articles

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Jingjing Feng, Heng Cao, Mingming Zhang, Xintong Feng, Shan Fu, Guoqing Wei, Ruimin Hong, Lianjun Shen, Jin Lin, Zhihong Liu, Jia Liu, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 2384.

https://doi.org/10.1182/blood-2025-2384

Published: 2025

Journal Articles

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

Shuyang Wang, Qisan Wu, Mengmeng Huang, Mingming Zhang, Shan Fu, Tingting Yang, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 2381.

https://doi.org/10.1182/blood-2025-2381

Published: 2025

Journal Articles

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

Yiqing Ren, Weiming Zhang, Guoqing Wei, Mingming Zhang, Shan Fu, Jingjing Feng, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 5941.

https://doi.org/10.1182/blood-2025-5941

Published: 2025

Journal Articles

Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study

Lianxuan Liu, Mingming Zhang, Houli Zhao, Guoqing Wei, Alex H. Zhang, He Huang, Yongxian Hu

Blood (2025) 146 (Supplement 1): 4161.

https://doi.org/10.1182/blood-2025-4161

Published: 2025

Journal Articles

Long term remission and survival in patients with relapsed or refractory non-Hodgkin lymphoma after treatment of brl-201, a CRISPR-based non-viral PD-1 locus specifically integrated anti-CD19 CAR-T cells: 4-year follow-up of a first-in-human phase I study

Yongxian Hu, Qian Tan, Jiqin Zhang, Mingming Zhang, Wenjun Wu, Guoqing Wei, Binghe Tan, Jiazhen Cui, Yuxuan Wu, Dali Li, Bing Du, Mingyao Liu, He Huang

Blood (2025) 146 (Supplement 1): 5930.

https://doi.org/10.1182/blood-2025-5930

Published: 2025

Journal Articles

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Haiqiong Zheng, Houli Zhao, Xin Jin, Delin Kong, Ruirui Jing, Jiazhen Cui, Simao Huang, Mingming Zhang, Jingjing Feng, Shan Fu, Guoqing Wei, Alex H Chang, Dongrui Wang, Yongxian Hu, He Huang

Blood (2025) 146 (Supplement 1): 5900.

https://doi.org/10.1182/blood-2025-5900

Published: 2025

Journal Articles

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2024) 144 (Supplement 1): 91.

https://doi.org/10.1182/blood-2024-210462

Published: 2024

Journal Articles

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Blood (2024) 144 (Supplement 1): 7420.

https://doi.org/10.1182/blood-2024-209418

Published: 2024

Journal Articles

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

Tingting Yang, Yetian Dong, Mingming Zhang, Jingjing Feng, Shan Fu, Pingnan Xiao, Ruimin Hong, Huijun Xu, Jiazhen Cui, Simao Huang, Guoqing Wei, Alex H. Chang, He Huang, Yongxian Hu

Blood (2024) 144 (Supplement 1): 2818.

https://doi.org/10.1182/blood-2024-210124

Published: 2024

Journal Articles

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

Jinglei Yu, Fengmei Song, Mingming Zhang, Mingfeng Zhao, Wei Sang, Songfu Jiang, Lixin Wang, Xingbing Wang, He Huang, Yongxian Hu, Guoqing Wei

Blood (2024) 144 (Supplement 1): 4201.

https://doi.org/10.1182/blood-2024-210616

Published: 2024

Journal Articles

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 101.

https://doi.org/10.1182/blood-2023-185236

Published: 2023

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Blood (2023) 142 (Supplement 1): 3579.

https://doi.org/10.1182/blood-2023-189068

Published: 2023

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors

Bingqian Jiang, Yanmin Zhao, Yi Luo, Jian Yu, Yi Chen, Baodong Ye, Huarui Fu, Xiaoyu Lai, Lizhen Liu, Yishan Ye, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi

Blood (2023) 142 (Supplement 1): 2243.

https://doi.org/10.1182/blood-2023-182809

Published: 2023

Journal Articles

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

Meng Liu, Xiaoli Wang, Yi Luo, Yanmin Zhao, Jian Yu, Xiaoyu Lai, Lizhen Liu, Huarui Fu, Weiyan Zheng, Jie Sun, Jingsong He, Yi Zhao, Guoqing Wei, Zhen Cai, He Huang, Jimin Shi

Blood (2023) 142 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2023-184513

Published: 2023

Journal Articles

Hyperleukocytosis Does Not Present a Worse Prognosis in Acute Myeloid Leukemia (Non-APL) with Favorable Risk According to ELN-2022 Criteria: A Retrospective Study

Shuyue Bao, Jinya Lin, Yuanyuan Zhu, Weijia Huang, Weiyan Zheng, Guoqing Wei, Zhen Cai, Yi Luo, Yi Zhao, Jimin Shi, He Huang, Jie Sun

Blood (2023) 142 (Supplement 1): 5867.

https://doi.org/10.1182/blood-2023-186943

Published: 2023

Journal Articles

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Blood (2023) 142 (Supplement 1): 2228.

https://doi.org/10.1182/blood-2023-184668

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis

Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies

Rituximab, lenalidomide, and zanubrutinib (ZR2) with sequential CAR-T cell as first-line therapy for high-risk large B cell lymphoma

One-year follow-up of CD19/BCMA dual-targeting fastcar-T GC012F (AZD0120) therapy in patients with refractory systemic lupus erythematosus

Immune remodeling enables sustained EBV clearance in B-cell and plasma cell malignancies after anti-CD19/BCMA CAR-T therapy: A post-hoc analysis

Donor-derived secondary CAR-T cell therapy for relapsed leukemia following initial CAR-T bridged to allogeneic transplantation: Efficacy and safety analysis

Anti-CD7 CAR-T cells in patients with relapsed or refractory CD7+ Acute Myeloid Leukemia: First-in-human phase I study

Long term remission and survival in patients with relapsed or refractory non-Hodgkin lymphoma after treatment of brl-201, a CRISPR-based non-viral PD-1 locus specifically integrated anti-CD19 CAR-T cells: 4-year follow-up of a first-in-human phase I study

CD7-negative T cell immune reconstitution after CD7-targted CAR-T cell therapy

Rituximab, Lenalidomide, and Zanubrutinib (ZR 2) with Sequential CAR-T Cell As First-Line Therapy for High-Risk Large B Cell Lymphoma

Long-Term Follow-up of Sequential Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients Achieving MRD-Negative CR after CAR-T Therapy

Sequential CD19 and CD22 CAR-T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia

CD19 CAR-T Therapy for Patients with Relapsed or Refractory Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia: A Multicenter Study

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

IPSS-M Predicts Survival Outcomes Significantly Better Than IPSS-R in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasms

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia Harboring KMT2A Rearrangement and Its Prognostic Factors

A Single Center Retrospective Study on the Efficacy of Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Myeloid Neoplasms over 50 Years Old

Hyperleukocytosis Does Not Present a Worse Prognosis in Acute Myeloid Leukemia (Non-APL) with Favorable Risk According to ELN-2022 Criteria: A Retrospective Study

Impact of TP53 Allelic State on Outcomes of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Neoplasm

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only